It was Christmas Eve, 1996. The pain had become excruciating—it had to be for Kerby to opt to go to the hosÂpital on Christmas Eve because Kerby’s pain tolerance was high. At that point, he had been living with what had ultimately been diagnosed as psoriatic arthritis for about 30 years. That Christmas Eve, the…
The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…
Michael B. Brenner, MD, addresses exciting advances in basic science in rheumatology, including insights into inflammation in osteoarthritis, the adult-onset autoinflammatory syndrome VEXAS and more.
In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…
Over the past 16 months, the world has shone a bright light on the importance of diversity, equity and inclusion (DEI). Although the College has been focused on diversity initiatives since 2020, the interprofessional division of the College, the ARP, has recently taken a deeper dive into DEI initiatives in its processes, procedures and volunteering….
The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…
Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes.
Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).
Contraception, disease control, family planning and managing life with an infant—five experts addressed these concerns and more for patients with rheumatic disease during a special online webinar.